Virus like particles as a platform for cancer vaccine development

PeerJ

Volumn 2017, Issue 11, 2017, Pages

  Ong, Hui Kian ^a   Tan, Wen Siang ^a   Ho, Kok Lian ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Cancer vaccine; Cytotoxic lymphocyte; Oncovirus; Tumor antigen; Vaccine development; Virus like particles; VLP based vaccine

Indexed keywords

CANCER VACCINE;

ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CELL DESTRUCTION; CYTOTOXIC LYMPHOCYTE; GENETIC ENGINEERING; HEPATITIS B; HEPATITIS C; INFLAMMATION; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN TRANSPORT; SKIN CANCER; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; VACCINE IMMUNOGENICITY; VIRAL CLEARANCE; VIRUS LIKE AGENT;

EID: 85034091286     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.4053     Document Type: Article

References (152)

1. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. 2008. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biology 10:619-624 DOI 10.1038/ncb1725
2. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. 2014. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. American Journal of Gastroenterology 109:542-553 DOI 10.1038/ajg.2014.11
3. Alter MJ. 2006. Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatol-ogy 44:S6-S9 DOI 10.1016/j.jhep.2005.11.004
4. Arbuthnot P, Capovilla A, Kew M. 2000. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. Journal of Gastroenterology and Hepatology 15:357-368 DOI 10.1046/j.1440-1746.2000.02069.x
5. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. 1987. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. Journal of Virology 61:962-971
6. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF. 2005. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105:3605-3614 DOI 10.1182/blood-2004-05-1952
7. Beaumont E, Roingeard P. 2013. Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Human Vaccines & Immunotherapeutics 9:1112-1118 DOI 10.4161/hv.23900
8. Biabanikhankahdani R, Alitheen NB, Ho KL, Tan WS. 2016. pH-responsive virus-like nanoparticles with enhanced tumour-targeting ligands for cancer drug delivery. Scientific Reports 6:37891 DOI 10.1038/srep37891
9. Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, Reiser CO, Hess J. 2005. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunology and Immunotherapy 54:611-622 DOI 10.1007/s00262-004-0655-0
10. Castiblanco J, Anaya JM. 2015. Genetics and vaccines in the era of personalized medicine. Current Genomics 16:47-59 DOI 10.2174/1389202916666141223220551
11. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Che-ung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. 2006. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. Journal of Clinical Oncology 24:1169-1177 DOI 10.1200/JCO.2005.03.6830
12. Chang K, Pastan I. 1996. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proceedings of the National Academy of Sciences of the United States of America 93:136-140
13. Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, Luvison A, Roy S, Seethala RR, Nikiforova MN. 2015. Molecular characterization of apocrine salivary duct carcinoma. American Journal of Surgical Pathology 39:744-752 DOI 10.1097/PAS.0000000000000410
14. Chroboczek J, Szurgot I, Szolajska E. 2014. Virus-like particles as vaccine. Acta Biochim-ica Polonica 61:531-539
15. Crisci E, Barcena J, Montoya M. 2012. Virus-like particles: the new frontier of vaccines for animal viral infections. Veterinary Immunology and Immunopathology 148:211-225 DOI 10.1016/j.vetimm.2012.04.026
16. Cubas R, Li M, Chen C, Yao Q. 2009. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochimica Et Biophysica Acta: Reviews on Cancer 1796:309-314 DOI 10.1016/j.bbcan.2009.08.001
17. Cubas R, Zhang S, Li M, Chen C, Yao Q. 2011. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer. Journal of Immunotherapy 34:251-263 DOI 10.1097/CJI.0b013e318209ee72
18. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. 2006. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Letters 236:229-238 DOI 10.1016/j.canlet.2005.05.021
19. Cuzick J. 2015. Gardasil 9 joins the fight against cervix cancer. Expert Review of Vaccines 14:1047-1049 DOI 10.1586/14760584.2015.1051470
20. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. 2003. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. Journal of Virology 77:1551-1563 DOI 10.1128/JVI.77.2.1551-1563.2003
21. De Martel C, Franceschi S. 2009. Infections and cancer: established associations and new hypotheses. Critical Reviews in Oncology/Hematology 70:183-194 DOI 10.1016/j.critrevonc.2008.07.021
22. Dimberu PM, Leonhardt RM. 2011. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale Journal of Biology and Medicine 84:371-380
23. Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW, Sun SH. 2009. Multiepitope peptideloaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49:1492-1502 DOI 10.1002/hep.22816
24. Drake 3rd DR, Moser JM, Hadley A, Altman JD, Maliszewski C, Butz E, Lukacher AE. 2000. Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes. Journal of Virology 74:4093-4101
25. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. 2007. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America 104:8427-8432 DOI 10.1073/pnas.0702162104
26. Eriksson M, Andreasson K, Weidmann J, Lundberg K, Tegerstedt K, Dalianis T, Ramqvist T. 2011. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLOS ONE 6:e23828 DOI 10.1371/journal.pone.0023828
27. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. 2013. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 49:1374-1403 DOI 10.1016/j.ejca.2012.12.027
28. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. 2008. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. British Journal of Cancer 99:1290-1295 DOI 10.1038/sj.bjc.6604677
29. Frierson Jr HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. 2003. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Human Pathology 34:605-609 DOI 10.1016/S0046-8177(03)00177-1
30. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. 2007. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. Journal of Virology 81:11585-11592 DOI 10.1128/JVI.01577-07
31. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chene I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Science Translational Medicine 3:Article 94ra71 DOI 10.1126/scitranslmed.3002330
32. Gheysen D, Jacobs E, De Foresta F, Thiriart C, Francotte M, Thines D, De Wilde M. 1989. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59:103-112 DOI 10.1016/0092-8674(89)90873-8
33. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kundig TM, Michielin O, Bachmann MF, Speiser DE. 2012. Nano-particle vaccination combined with TLR-7 and-9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. European Journal of Immunology 42:3049-3061 DOI 10.1002/eji.201142361
34. Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. 2016. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer-a case report and review. BMC Cancer 16:786 DOI 10.1186/s12885-016-2821-0
35. Gould SJ, Raposo G. 2013. As we wait: coping with an imperfect nomenclature for extracellular vesicles. Journal of Extracellular Vesicles 2:Article 20389 DOI 10.3402/jev.v2i0.20389
36. Graff JN, Chamberlain ED. 2015. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evidence 10:1-10 DOI 10.2147/CE.S54712
37. Graham SV. 2010. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiology 5:1493-1506 DOI 10.2217/fmb.10.107
38. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Con-nor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS. 2006. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Molecular Cancer 5:Article 50 DOI 10.1186/1476-4598-5-50
39. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. 2013. Therapeutic cancer vaccines: past, present, and future. Advances in Cancer Research 119:421-475 DOI 10.1016/B978-0-12-407190-2.00007-1
40. Haynes JR. 2009. Influenza virus-like particle vaccines. Expert Review of Vaccines 8:435-445 DOI 10.1586/erv.09.8
41. Herzenberg LA, Tokuhisa T. 1982. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. Journal of Experimetnal Medicine 155:1730-1740 DOI 10.1084/jem.155.6.1730
42. Hjalgrim H, Friborg J, Melbye M. 2007. The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press
43. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. 2007. Mesothelin expression in human lung cancer. Clinical Cancer Research 13:1571-1575 DOI 10.1158/1078-0432.CCR-06-2161
44. Howard CR, Allison LMC. 1995. Hepatitis B surface antigen variation and protective immunity. Intervirology 38:35-40 DOI 10.1159/000150412
45. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD. 1996. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Molecular and Cellular Biology 16:952-959 DOI 10.1128/MCB.16.3.952
46. Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R. 2015. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLOS ONE 10:e0120152 DOI 10.1371/journal.pone.0120152
47. Jeang KT. 2010. HTLV-1 and adult T-cell leukemia: insights into viral transformation of cells 30 years after virus discovery. Journal of the Formosan Medical Association 109:688-698 DOI 10.1016/S0929-6646(10)60112-X
48. Jegerlehner A, Wiesel M, Dietmeier K, Zabel F, Gatto D, Saudan P, Bachmann MF. 2010. Carrier induced epitopic suppression of antibody responses induced by viruslike particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 28:5503-5512 DOI 10.1016/j.vaccine.2010.02.103
49. Jemon K, Young V, Wilson M, McKee S, Ward V, Baird M, Young S, Hibma M. 2013. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLOS ONE 8:e66866 DOI 10.1371/journal.pone.0066866
50. Jennings GT, Bachmann MF. 2008. The coming of age of virus-like particle vaccines. Biological Chemistry 389:521-536 DOI 10.1515/BC.2008.064
51. Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ. 2004. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. Journal of Virology 78:6995-7003 DOI 10.1128/JVI.78.13.6995-7003.2004
52. Jochum S, Ruiss R, Moosmann A, Hammerschmidt W, Zeidler R. 2012. RNAs in Epstein-Barr virions control early steps of infection. Proceedings of the Na-tional Academy of Sciences of the United States of America 109:E1396-E1404 DOI 10.1073/pnas.1115906109
53. Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P. 2008. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnology Journal 3:1429-1436 DOI 10.1002/biot.200800160
54. Khan KH. 2013. Gene expression in Mammalian cells and its applications. Advanced Pharmaceutical Bulletin 3:257-263 DOI 10.5681/apb.2013.042
55. Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. 2014. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 120:3058-3065 DOI 10.1002/cncr.28843
56. Kjerrulf M, Lowenadler B, Svanholm C, Lycke N. 1997. Tandem repeats of T helper epitopes enhance immunogenicity of fusion proteins by promoting processing and presentation. Molecular Immunology 34:599-608
57. Klamp T, Schumacher J, Huber G, Kuhne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Tureci O, Sahin U. 2011. Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Research 71:516-527 DOI 10.1158/0008-5472.CAN-10-2292
58. Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y. 2015. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. International Journal of Clinical Oncology 20:176-181 DOI 10.1007/s10147-014-0696-0
59. Kourembanas S. 2015. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annual Review of Physiology 77:13-27 DOI 10.1146/annurev-physiol-021014-071641
60. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. 2009. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. Journal of Experimetnal Medicine 206:1327-1337 DOI 10.1084/jem.20082173
61. Kushnir N, Streatfield SJ, Yusibov V. 2012. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58-83 DOI 10.1016/j.vaccine.2012.10.083
62. Laheru D, Jaffee EM. 2005. Immunotherapy for pancreatic cancer-science driving clinical progress. Nature Reviews Cancer 5:459-467 DOI 10.1038/nrc1630
63. Lavanchy D. 2005. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of Clinical Virology 34(Suppl 1):S1-S3 DOI 10.1016/S1386-6532(05)00384-7
64. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. 2001. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34:417-423 DOI 10.1053/jhep.2001.26523
65. Lee KW, Tey BT, Ho KL, Tejo BA, Tan WS. 2012. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery. Molecular Pharmacology 9:2415-2423 DOI 10.1021/mp200389t
66. Li K, Peers-Adams A, Win SJ, Scullion S, Wilson M, Young VL, Jennings P, Ward VK, Baird MA, Young SL. 2013. Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo. Journal of Immunotherapy 36:11-19 DOI 10.1097/CJI.0b013e3182787f5e
67. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q. 2008. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Molecular Cancer Therapeutics 7:286-296 DOI 10.1158/1535-7163.MCT-07-0483
68. Liu JKH. 2014. Anti-cancer vaccines-a one-hit wonder? Yale Journal of Biology and Medicine 87:481-489
69. Ljubojevic S, Skerlev M. 2014. HPV-associated diseases. Clinics in Dermatology 32:227-234 DOI 10.1016/j.clindermatol.2013.08.007
70. Lollini PL, Cavallo F, Nanni P, Forni G. 2006. Vaccines for tumour prevention. Nature Reviews Cancer 6:204-216 DOI 10.1038/nrc1815
71. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. 2012. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 156:271-278 DOI 10.7326/0003-4819-156-4-201202210-00004
72. Ma B, Roden R, Wu TC. 2010. Current status of human papillomavirus vaccines. Journal of the Formosan Medical Association 109:481-483 DOI 10.1016/S0929-6646(10)60081-2
73. Madrid-Marina V, Torres-Poveda K, Lopez-Toledo G, Garcia-Carranca A. 2009. Advantages and disadvantages of current prophylactic vaccines against HPV. Archives of Medical Research 40:471-477 DOI 10.1016/j.arcmed.2009.08.005
74. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. 1998. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. Journal of Immunology 161:6532-6536
75. Markopoulos C, Tsaroucha AK, Kouskos E, Mantas D, Antonopoulou Z, Karvelis S. 2009. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. Journal of International Medical Research 37:182-188 DOI 10.1177/147323000903700122
76. Martin Caballero J, Garzon A, Gonzalez-Cintado L, Kowalczyk W, Jimenez Torres I, Calderita G, Rodriguez M, Gondar V, Bernal JJ, Ardavin C, Andreu D, Zurcher T, Von Kobbe C. 2012. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. PLOS ONE 7:e52976 DOI 10.1371/journal.pone.0052976
77. McCarthy EF. 2006. The toxins of William B. Coley and the treatment of bone and softtissue sarcomas. Iowa Orthopedic Journal 26:154-158
78. McKee SJ, Young VL, Clow F, Hayman CM, Baird MA, Hermans IF, Young SL, Ward VK. 2012. Virus-like particles and alpha-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. Journal of Controlled Release 159:338-345 DOI 10.1016/j.jconrel.2012.02.015
79. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. 2014. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26:707-721 DOI 10.1016/j.ccell.2014.09.005
80. Meza-Junco J, Au HJ, Sawyer MB. 2011. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Management and Research 3:57-64 DOI 10.2147/CMR.S12698
81. Micallef JM, Kaldor JM, Dore GJ. 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 13:34-41 DOI 10.1111/j.1365-2893.2005.00651.x
82. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. 2008. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Practice & Research Clinical Endocrinology & Metabolism 22:341-355 DOI 10.1016/j.beem.2008.01.011
83. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. 2003. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virusvaccinia infection. Proceedings of the National Academy of Sciences of the United States of America 100:6753-6758 DOI 10.1073/pnas.1131929100
84. Narayanan DL, Saladi RN, Fox JL. 2010. Ultraviolet radiation and skin cancer. Interna-tional Journal of Dermatology 49:978-986 DOI 10.1111/j.1365-4632.2010.04474.x
85. Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends in Microbiology 11:438-444 DOI 10.1016/S0966-842X(03)00208-7
86. Nolte-'t Hoen E, Cremer T, Gallo RC, Margolis LB. 2016. Extracellular vesicles and viruses: are they close relatives? Proceedings of the National Academy of Sciences of the United States of America 113:9155-9161 DOI 10.1073/pnas.1605146113
87. Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH. 2009. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 113:1977-1981 DOI 10.1182/blood-2008-08-174094
88. Nour NM. 2009. Cervical cancer: a preventable death. Reviews in Obstetrics and Gynecol-ogy 2:240-244
89. Oberstein PE, Olive KP. 2013. Pancreatic cancer: why is it so hard to treat? Therapeutic Advances in Gastroenterology 6:321-337 DOI 10.1177/1756283X13478680
90. Ogembo JG, Muraswki MR, McGinnes LW, Parcharidou A, Sutiwisesak R, Tison T, Avendano J, Agnani D, Finberg RW, Morrison TG, Fingeroth JD. 2015. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. Journal of Translational Medicine 13:Article 50 DOI 10.1186/s12967-015-0415-2
91. Ohno S, Drummen GP, Kuroda M. 2016. Focus on extracellular vesicles: development of extracellular vesicle-based therapeutic systems. International Journal of Molecular Sciences 17:Article 172 DOI 10.3390/ijms17020172
92. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. 2017. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217-221 DOI 10.1038/nature22991
93. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer 118:3030-3044 DOI 10.1002/ijc.21731
94. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. 2005. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337:365-372 DOI 10.1016/j.virol.2005.04.011
95. Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P. 2015a. Protein transfer-mediated surface engineering to adjuvantate viruslike nanoparticles for enhanced anti-viral immune responses. Nanomedicine 11:1097-1107 DOI 10.1016/j.nano.2015.02.008
96. Patel JM, Vartabedian VF, Kim MC, He S, Kang SM, Selvaraj P. 2015b. Influenza viruslike particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnology and Bioengineering 112:1102-1110 DOI 10.1002/bit.25537
97. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 104:6025-6030 DOI 10.1073/pnas.0607026104
98. Pineo CB, Hitzeroth II, Rybicki EP. 2013. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnology Journal 11:964-975 DOI 10.1111/pbi.12089
99. Pleckaityte M, Bremer CM, Gedvilaite A, Kucinskaite-Kodze I, Glebe D, Zvirbliene A. 2015. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen. BMC Biotechnology 15:85 DOI 10.1186/s12896-015-0203-3
100. Poynard T, Yuen MF, Ratziu V, Lai CL. 2003. Viral hepatitis C. Lancet 362:2095-2100 DOI 10.1016/S0140-6736(03)15109-4
101. Psyrri A, DeFilippis RA, Edwards AP, Yates KE, Manuelidis L, DiMaio D. 2004. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Research 64:3079-3086
102. Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ. 2003. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 37:52-59 DOI 10.1053/jhep.2003.50000
103. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. 1996. B lymphocytes secrete antigen-presenting vesicles. Journal of Experimetnal Medicine 183:1161-1172 DOI 10.1084/jem.183.3.1161
104. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148:349-361 DOI 10.1016/j.cell.2011.11.025
105. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. 2003. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307-325 DOI 10.1634/theoncologist.8-4-307
106. Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. 2011. A virus-like particle-based Epstein-Barr virus vaccine. Journal of Virology 85:13105-13113 DOI 10.1128/JVI.05598-11
107. Ruiz-Tachiquin ME, Valdez-Salazar HA, Juarez-Barreto V, Dehesa-Violante M, Torres J, Munoz-Hernandez O, Alvarez-Munoz MT. 2007. Molecular analysis of hepatitis B virus ''a'' determinant in asymptomatic and symptomatic Mexican carriers. Virology Journal 4:Article 6 DOI 10.1186/1743-422X-4-6
108. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, Van de Vijver M, Viale G. 2012. HER2 testing in gastric cancer: a practical approach. Modern Pathology 25:637-650 DOI 10.1038/modpathol.2011.198
109. Rynda-Apple A, Patterson DP, Douglas T. 2014. Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. Nanomedicine 9:1857-1868 DOI 10.2217/nnm.14.107
110. Sannino G, Armbruster N, Bodenhofer M, Haerle U, Behrens D, Buchholz M, Roth-bauer U, Sipos B, Schmees C. 2016. Role of BCL9L in transforming growth factorbeta (TGF-beta)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget 7:73725-73738 DOI 10.18632/oncotarget.12455
111. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. 2008. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal of Gynaecology and Obstetrics 102:128-131 DOI 10.1016/j.ijgo.2008.04.008
112. Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK. 2001. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nature Biotechnology 19:760-764 DOI 10.1038/90816
113. Schaefer S, Seifer M, Grimmsmann T, Fink L, Wenderhold S, Hohne MW, Gerlich WH. 1998. Properties of tumour suppressor p53 in murine hepatocyte lines transformed by hepatitis B virus X protein. Journal of General Virology 79(Pt 4):767-777 DOI 10.1099/0022-1317-79-4-767
114. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. 2013. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. Journal of Investigative Dermatology 133:2706-2713 DOI 10.1038/jid.2013.253
115. Schirrmacher V, Fournier P. 2010. Danger signals in tumor cells: a risk factor for autoimmune disease? Expert Review of Vaccines 9:347-350 DOI 10.1586/erv.10.15
116. Schlom J. 2012. Therapeutic cancer vaccines: current status and moving forward. Journal of the National Cancer Institute 104:599-613 DOI 10.1093/jnci/djs033
117. Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. 2012. Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. Medicinal Research Reviews 32:1197-1219 DOI 10.1002/med.20237
118. Simoes MC, Sousa JJ, Pais AA. 2015. Skin cancer and new treatment perspectives: a review. Cancer Letters 357:8-42 DOI 10.1016/j.canlet.2014.11.001
119. Somi MH, Etemadi J, Ghojazadeh M, Farhang S, Faramarzi M, Foroutan S, Soleiman-pour M. 2014. Risk factors of HCV seroconversion in hemodialysis patients in tabriz, iran. Hepatitis Monthly 14:e17417 DOI 10.5812/hepatmon.17417
120. Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, Gruhn B, Pastan I. 2007. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. European Journal of Haematology 79:281-286 DOI 10.1111/j.1600-0609.2007.00928.x
121. Steinmetz NF, Mertens ME, Taurog RE, Johnson JE, Commandeur U, Fischer R, Manchester M. 2010. Potato virus X as a novel platform for potential biomedical applications. Nano Letters 10:305-312 DOI 10.1021/nl9035753
122. Stickney Z, Losacco J, McDevitt S, Zhang Z, Lu B. 2016. Development of exosome surface display technology in living human cells. Biochemical and Biophysical Research Communications 472:53-59 DOI 10.1016/j.bbrc.2016.02.058
123. Strassburg MA. 1982. The global eradication of smallpox. American Journal of Infection Control 10:53-59
124. Su Q, Schroder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. 1998. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology 27:1109-1120 DOI 10.1002/hep.510270428
125. Tan WS, Ho KL. 2014. Phage display creates innovative applications to combat hepatitis B virus. World Journal of Gastroenterology 20:11650-11670 DOI 10.3748/wjg.v20.i33.11650
126. Tegerstedt K, Franzen A, Ramqvist T, Dalianis T. 2007. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunology and Immunotherapy 56:1335-1344 DOI 10.1007/s00262-007-0281-8
127. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalia-nis T, Kiessling R, Ramqvist T. 2005. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Research 65:5953-5957 DOI 10.1158/0008-5472.CAN-05-0335
128. Terpe K. 2006. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Ap-plied Microbiology and Biotechnology 72:211-222 DOI 10.1007/s00253-006-0465-8
129. Thompson MP, Kurzrock R. 2004. Epstein-Barr virus and cancer. Clinical Cancer Research 10:803-821 DOI 10.1158/1078-0432.CCR-0670-3
130. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K, Group HSS. 2013. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. International Journal of Cancer 132:854-867 DOI 10.1002/ijc.27713
131. Tominaga N, Yoshioka Y, Ochiya T. 2015. A novel platform for cancer therapy using extracellular vesicles. Advanced Drug Delivery Reviews 95:50-55 DOI 10.1016/j.addr.2015.10.002
132. Tomura M, Yu WG, Ahn HJ, Yamashita M, Yang YF, Ono S, Hamaoka T, Kawano T, Taniguchi M, Koezuka Y, Fujiwara H. 1999. A novel function of Valpha14+ CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. Journal of Immunology 163:93-101
133. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65:87-108 DOI 10.3322/caac.21262
134. Tyler M, Tumban E, Chackerian B. 2014. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Review of Vaccines 13:247-255 DOI 10.1586/14760584.2014.865523
135. Vietheer PT, Boo I, Drummer HE, Netter HJ. 2007. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antiviral Therapy 12:477-487
136. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM. 2009. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Annals of the New York Academy of Sciences 1174:6-17 DOI 10.1111/j.1749-6632.2009.04933.x
137. Wang JW, Roden RB. 2013. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Review of Vaccines 12:129-141 DOI 10.1586/erv.12.151
138. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. 2017. Role of tumor microenvironment in tumorigenesis. Journal of Cancer 8:761-773 DOI 10.7150/jca.17648
139. Williams CB, Yeh ES, Soloff AC. 2016. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer 2:Article 15025 DOI 10.1038/npjbcancer.2015.25
140. Wilt TJ, Ahmed HU. 2013. Prostate cancer screening and the management of clinically localized disease. BMJ 346:Article f325 DOI 10.1136/bmj.f325
141. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Medicine 7:297-303 DOI 10.1038/85438
142. Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. 2012. Extracellular vesicles and their convergence with viral pathways. Advances in Virology 2012:Article 767694 DOI 10.1155/2012/767694
143. Yan D, Wei YQ, Guo HC, Sun SQ. 2015. The application of virus-like particles as vaccines and biological vehicles. Applied Microbiology and Biotechnology 99:10415-10432 DOI 10.1007/s00253-015-7000-8
144. Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C. 2000. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Research and Human Retroviruses 16:227-236 DOI 10.1089/088922200309322
145. Ye L, Dong N, Wang Q, Xu Z, Cai N, Wang H, Zhang X. 2008. Progressive changes in hepatoma cells stably transfected with hepatitis B virus X gene. Intervirology 51:50-58 DOI 10.1159/000120289
146. Yim EK, Park JS. 2005. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Research and Treatment 37:319-324 DOI 10.4143/crt.2005.37.6.319
147. Yong CY, Yeap SK, Goh ZH, Ho KL, Omar AR, Tan WS. 2015a. Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus. Applied and Environmental Microbiology 81:882-889 DOI 10.1128/AEM.03695-14
148. Yong CY, Yeap SK, Ho KL, Omar AR, Tan WS. 2015b. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles. International Journal of Nanomedicine 10:2751-2763 DOI 10.2147/IJN.S77405
149. Zhang S, Yong LK, Li D, Cubas R, Chen C, Yao Q. 2013. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS-regulatory T cells. PLOS ONE 8:e68303 DOI 10.1371/journal.pone.0068303
150. Zhang Y, Song S, Liu C, Wang Y, Xian X, He Y, Wang J, Liu F, Sun S. 2007. Generation of chimeric HBc proteins with epitopes in E. coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cellular Immunology 247:18-27 DOI 10.1016/j.cellimm.2007.07.003
151. Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, Chalmers J, Schmittgen TD, Phelps MA. 2017. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles 6:Article 1324730 DOI 10.1080/20013078.2017.1324730
152. zur Hausen H. 2001. Oncogenic DNA viruses. Oncogene 20:7820-7823 DOI 10.1038/sj.onc.1204958